256 related articles for article (PubMed ID: 24550252)
1. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
3. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
[TBL] [Abstract][Full Text] [Related]
4. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V
Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672
[TBL] [Abstract][Full Text] [Related]
5. miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes.
Hung PS; Liu CJ; Chou CS; Kao SY; Yang CC; Chang KW; Chiu TH; Lin SC
PLoS One; 2013; 8(11):e79926. PubMed ID: 24302991
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
7. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
8. Differences in microRNA expression between melanoma and healthy adjacent skin.
Aksenenko M; Palkina N; Komina A; Tashireva L; Ruksha T
BMC Dermatol; 2019 Jan; 19(1):1. PubMed ID: 30611259
[TBL] [Abstract][Full Text] [Related]
9. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival.
Mahapatra L; Andruska N; Mao C; Gruber SB; Johnson TM; Fullen DR; Raskin L; Shapiro DJ
Melanoma Res; 2019 Oct; 29(5):539-543. PubMed ID: 30543563
[TBL] [Abstract][Full Text] [Related]
13. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
14. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.
D'Aguanno S; Valentini E; Tupone MG; Desideri M; Di Martile M; Spagnuolo M; Buglioni S; Ercolani C; Falcone I; De Dominici M; Milella M; Rizzo MG; Calabretta B; Cota C; Anichini A; Trisciuoglio D; Del Bufalo D
J Exp Clin Cancer Res; 2018 Nov; 37(1):278. PubMed ID: 30454024
[TBL] [Abstract][Full Text] [Related]
15. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
[TBL] [Abstract][Full Text] [Related]
17. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
18. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways.
Liu S; Gao G; Yan D; Chen X; Yao X; Guo S; Li G; Zhao Y
Cancer Med; 2017 Apr; 6(4):819-833. PubMed ID: 28332309
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
20. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
